Scarica l'app Stockscreener
305.54
2.63%
-8.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$313.79
Aprire:
$309.63
Volume 24 ore:
817.20K
Relative Volume:
0.65
Capitalizzazione di mercato:
$40.77B
Reddito:
$3.71B
Utile/perdita netta:
$313.75M
Rapporto P/E:
135.37
EPS:
2.2571
Flusso di cassa netto:
$465.38M
1 W Prestazione:
-1.33%
1M Prestazione:
-0.81%
6M Prestazione:
-34.07%
1 anno Prestazione:
+25.94%
Intervallo 1D:
$302.89
$311.10
Intervallo di 1 settimana:
$301.63
$315.83
Portata 52W:
$240.00
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-07 | Ripresa | Oppenheimer | Outperform |
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - MSN
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
JP Morgan Maintains Alnylam Pharmaceuticals (ALNY) Overweight Recommendation - MSN
Do options traders know something about Alnylam Pharmaceuticals stock we don't? - MSN
Bernstein SocGen cuts Alnylam stock price target on Amvuttra focus By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals: Cutting-Edge Pharma Stock Still Feels A Little Overvalued (ALNY) - Seeking Alpha
Why Alnylam (ALNY) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
ALNY Q4 earnings beat, sales miss despite Y/Y growth, stock down - MSN
Alnylam Pharmaceuticals (ALNY) Expected to Announce Earnings on Thursday - MarketBeat
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As Growth Momentum Cools After Multi Year Gains - simplywall.st
Alnylam Pharmaceuticals, Inc.Common Stock (NQ: ALNY - FinancialContent
Alnylam Pharmaceuticals (XTER:DUL) Short-term investments - GuruFocus
Alnylam Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Alnylam Pharmaceuticals (ALNY) presents Vutrisiran ATTR-CM data at ACC.26 - MSN
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today - Benzinga
Zurcher Kantonalbank Zurich Cantonalbank Buys 48,860 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Truist Lowers PT on Alnylam Pharmaceuticals (ALNY) to $505 From $515 - Insider Monkey
Alnylam Pharmaceuticals (ALNY) Stock Analysis: A 45% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Assetmark Inc. Has $6.38 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Emerges as a Top GARP Stock Pick - ChartMill
GF Fund Management CO. LTD. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Choppy Trading And Rich P/E Multiple - Yahoo Finance
RNAi Technology Market to Reach USD 9.58 Billion by 2033 at 15.26% - openPR.com
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results - BioSpace
Alnylam (ALNY) slides 4% as valuation concerns linger after recent analyst reset - Quiver Quantitative
KBC Group NV Has $138.46 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Wells Fargo raises Alnylam (ALNY) revenue estimates for Amvuttra despite projected margin compression - MSN
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? - Eastern Progress
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock? - Eastern Progress
Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates - Eastern Progress
Did New Vutrisiran Data and FCF Breakeven Just Shift Alnylam Pharmaceuticals' (ALNY) Investment Narrative? - simplywall.st
Robeco Institutional Asset Management B.V. Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Truist Financial Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $505.00 - MarketBeat
Whats the beta of Alnylam Pharmaceuticals Inc stockWeekly Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
Massachusetts Financial Services Co. MA Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Trimmed by Baillie Gifford & Co. - MarketBeat
Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference - Yahoo
Is Alnylam Pharmaceuticals (ALNY) The Best Growth Stock? - Insider Monkey
A Look At Alnylam Pharmaceuticals’ (ALNY) Valuation After Recent Mixed Share Price Performance - simplywall.st
10 Best Growth Stocks to Buy With Highest Upside Potential - Insider Monkey
Alnylam Achieves Leading Trading Position Despite Declining Volume as Revenue Surges - Bitget
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.33%
0.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):